Dr. Snyder is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 E Duarte Rd
Duarte, CA 91010Phone+1 626-359-8111- Is this information wrong?
Education & Training
- Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1984
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1978 - 1980
- New York Presbyterian Hospital (Columbia Campus)Internship, Internal Medicine, 1977 - 1978
- Harvard Medical SchoolClass of 1977
Certifications & Licensure
- CA State Medical License 1984 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Clinical Trials
- A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
- Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- 7 citationsOutcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL.Ibrahim Aldoss, Dongyun Yang, Vanina Tomasian, Sally Mokhtari, Ryan Jackson, Zhaohui Gu, Milhan Telatar, Hooi Yew, Monzr M Al Malki, Amandeep Salhotra, Samer Khaled, H...> ;Blood Advances. 2022 Sep 13
- 4 citationsLong-Term Follow-Up of Multiple Myeloma Patients Treated with Tandem Autologous Transplantation Following Melphalan and Upon Recovery, Total Marrow Irradiation.Colton Ladbury, George Somlo, Andy Dagis, Dongyun Yang, Saro Armenian, Joo Y Song, Firoozeh Sahebi, Ricardo Spielberger, Leslie Popplewell, Pablo Parker, Stephen Forma...> ;Transplantation and Cellular Therapy. 2022 Jul 1
- 9 citationsPeritransplant Ruxolitinib Administration is Safe and Effective in Patients with Myelofibrosis: a Pilot Open-Label Study.Haris Ali, Ni-Chun Tsai, Timothy W. Synold, Sally Mokhtari, Weimin Tsai, Joycelynne Palmer, Tracey Stiller, Amandeep Salhotra, Syed Rahmanuddin, Vinod Pullarkat, Ji-Li...> ;Blood Advances. 2021 Sep 28
- Join now to see all
Abstracts/Posters
- Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administr...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Spred1 Insufficiency in the Hematopoietic and/or Vascular Compartments of the Bone Marrow (BM) Niche Promotes Aggressive Leukemogenesis in Chronic Myelogenous Leukemia...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...David Snyder, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- 2 City of Hope Physicians Recognized for Compassionate Patient Care, Innovative LeadershipDecember 8th, 2020
- Imetelstat Promising Across Myeloproliferative NeoplasmsSeptember 4th, 2015
Hospital Affiliations
- City of Hope Comprehensive Cancer CenterDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: